Rosenoff S H, Young R C, Chabner B, Hubbard S, De Vita V T, Schein P S
Natl Cancer Inst Monogr. 1975 Oct;42:81-6.
Forty patients with ovarian adenocarcinoma had peritoneoscopy within 1 month of their exploratory laparotomy as part of their pretreatment evaluation. Of 12 patients (58%) believed to have disease localized to the pelvis (stage 1 or II) at laparotomy staging 7 were found to have more advanced disease (stage III) at peritoneoscopy and thus required a change in therapy. Involvement of the diaphragm with metastatic ovarian carcinoma was found in 63% of all patients. This finding again necessitated a change in therapy, since the right hemidiaphragm is shielded along with the liver when abdominal radiotherapy is used. Peritoneoscopy supplied the only followable findings with which to gauge response to therapy in 40% of the patients and also supplied followable findings in 78% of all patients studied. Second-look peritoneoscopy was performed in all patients achieving an apparent clinical remission with chemotherapy. Active disease was found in 43% of these patients, which thus precluded the need for laparotomy.
40例卵巢腺癌患者在剖腹探查术1个月内接受了腹腔镜检查，作为其预处理评估的一部分。在剖腹探查分期时被认为疾病局限于盆腔（Ⅰ期或Ⅱ期）的12例患者（58%）中，7例在腹腔镜检查时被发现疾病进展至更晚期（Ⅲ期），因此需要改变治疗方案。在所有患者中，63%发现有转移性卵巢癌累及膈肌。这一发现再次需要改变治疗方案，因为使用腹部放疗时，右半膈肌与肝脏一起受到保护。在40%的患者中，腹腔镜检查提供了唯一可追踪的结果来评估治疗反应，并且在所有接受研究的患者中，78%的患者也获得了可追踪的结果。所有经化疗达到明显临床缓解的患者均进行了二次腹腔镜检查。在这些患者中，43%发现有活动性疾病，因此无需进行剖腹手术。
